Price
$57.65
Decreased by -3.39%
Dollar Volume
47.49 M
ADR%
5.15
Earnings Report Date (estimate)
Feb 22, 23 (-0.24)
Market Cap.
2.86 B
Shares Float
49.13 M
Shares Outstanding
49.53 M
Beta
0.43
Price / Earnings
-31.94
BPR
71.89
20D Range
54.57 68.05
50D Range
54.57 71.99
200D Range
38.41 79.92
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Oct 31, 22 -0.34
Increased by +10.53%
-0.48
Increased by +29.17%
Aug 1, 22 -0.47
Increased by +20.34%
-0.54
Increased by +12.96%
May 5, 22 -0.50
Increased by +12.28%
-0.63
Increased by +20.63%
Feb 24, 22 -0.34
Decreased by -17.24%
-0.37
Increased by +8.11%
Nov 4, 21 -0.38
Decreased by -58.33%
-0.43
Increased by +11.63%
Aug 5, 21 -0.59
Decreased by -9.26%
-0.49
Decreased by -20.41%
May 6, 21 -0.57
Decreased by -32.56%
-0.41
Decreased by -39.02%
Feb 25, 21 -0.29
Increased by +61.33%
-0.31
Increased by +6.45%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 70.38 M
Increased by +50.03%
-16.25 M
Increased by +5.79%
Decreased by -23.09%
Increased by +37.20%
Jun 30, 22 68.98 M
Increased by +50.38%
-21.44 M
Increased by +14.73%
Decreased by -31.09%
Increased by +43.30%
Mar 31, 22 48.42 M
Increased by +40.87%
-22.67 M
Decreased by -0.73%
Decreased by -46.82%
Increased by +28.49%
Dec 31, 21 53.13 M
Increased by +52.76%
-15.17 M
Decreased by -33.64%
Decreased by -28.54%
Increased by +12.51%
Sep 30, 21 46.91 M
Increased by +33.11%
-17.25 M
Decreased by -88.15%
Decreased by -36.77%
Decreased by -41.35%
Jun 30, 21 45.87 M
Increased by +201.51%
-25.15 M
Decreased by -27.12%
Decreased by -54.83%
Increased by +57.84%
Mar 31, 21 34.37 M
Increased by +30.72%
-22.50 M
Decreased by -53.96%
Decreased by -65.47%
Decreased by -17.78%
Dec 31, 20 34.78 M
Increased by +249.72%
-11.35 M
Increased by +50.12%
Decreased by -32.63%
Increased by +85.74%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.